• Hussein Kadhem Al-hakeim Professor in Medical Biochemistry, Department of Chemistry, Faculty of Science, Kufa University, Iraq
  • Iman Muhammed Jebur Kufa University
  • Ali Ibrahim Rahim Kufa University


Objective: In vitro fertilization (IVF) is an important tool and it is widely used in the treatment of infertility. However, the failure rate is still high. Thus the study of the factors affecting the rate of success of IVF cycles is very important field of study. In the present study, the possible relationship between the Sirtuin-6 (SIRT6), a stress-responsive protein deacetylase, and the outcome of IVF was studied. SIRT6 also was correlated with hormone levels in women with IVF failure.

Methods: Sixty women undergo IVF patients were participated in the study. Women group that had conceived from IVF are expressed as "pregnant group" while women who hadn't are expressed as "failure group." All groups had same preparations and same treatment regimen.

Results: Results revealed that there is an insignificant difference between pregnant and failure groups in serum SIRT6 level. The results showed a significant higher estradiol, and lower prolactin and antimullerian hormone in pregnant in comparing with failure group. Correlations studies indicated no significant correlation between SIRT6 and hormones in pregnant group, while there is a significant correlation between SIRT6 and estradiol hormone in the failure group.

Conclusion: It can be concluded that serum SIRT6 level does not differ between women who had success or failure IVF. However, in women with failure, SIRT6 is correlated with estradiol level.


Keywords: In vitro fertilization, Estradiol, SIRT6


Download data is not yet available.


1. Cooper TG, Noonan E, Von Eckardstein S, Auger J, Baker HW, Behre HM, et al. World health organization reference values for human semen characteristics. Hum Reprod 2010;16:231-45.
2. Practice committee of american society for reproductive medicine. Definitions of infertility and recurrent pregnancy loss. Fertil Steril 2008;90:S60.
3. Legro RS. A 27-year-old woman with a diagnosis of polycystic ovary syndrome. JAMA 2007;297:509-19.
4. Luciano AA, Lanzone A, Goverde AJ. Management of female infertility from hormonal causes. Int J Gynecol Obstet 2013;123 Suppl 2:S9-17.
5. Fertility: assessment and treatment for people with fertility problems. NICE Clinical Guideline: Issued; 2013. p. 31-2.
6. Kovacs GT, Maclachlan V, Brehny S. What is the probability of conception for couples entering an IVF program? Aust N Z J Obstet Gynaecol 2001;41:207-9.
7. Kitada M, Kume S, Takeda-Watanabe A, Kanasaki K, Koya D. Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clin Sci (Lond) 2013;124:153-64.
8. Lombard DB, Schwer B, Alt FW, Mostoslavsky R. SIRT6 in DNA repair, metabolism and ageing. J Intern Med 2008;263:128–41.
9. Luo LL, Chen XC, Fu YC, Xu JJ, Li L, Lin XH, et al. The effects of caloric restriction and a high-fat diet on ovarian lifespan and the expression of SIRT1 and SIRT6 proteins in rats. Aging Clin Exp Res 2012;24:125-33.
10. Joo BS, Park SH, Min AB, Kim KS, Moon SE, Moon HS. Serum estradiol levels during controlled ovarian hyperstimulation influence the pregnancy outcome of in vitro fertilization in a concentration-dependent manner. Fertil Steril 2010;93:442-6.
11. Loutradis D, Beretsos P, Arabatzi E, Anagnostou E, Drakakis P. The role of steroid hormones in ART. J Steroid Biochem Mol Biol 2008;112:1–4.
12. DiLuigi AJ, Nulsen JC. Effects of gonadotropin-releasing hormone agonists and antagonists on luteal function. Current Opinion Obstetrics Gynecology 2007;19:258-65.
13. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin releasing hormone antagonists. Fertil Steril 2004;82:102-7.
14. Bourgain C, Ubaldi F, Tavaniotou A, Smitz J, Van Steirteghem AC, Devroey P. Endometrial hormone receptors and proliferation index in the periovulatory phase of stimulated embryo transfer cycles in comparison with natural cycles and relation to clinical pregnancy outcome. Fertil Steril 2002;78:237-43.
15. Mendoza C, Ruiz-Requena E, Ortega E, Cremades N, Martinez F, Bernabeu R, et al. Follicular fluid markers of oocyte developmental potential. Hum Reprod 2002;17:1017-22.
16. Valbuena D, Martin J, de Pablo JL, Remohi J, Pellicer A, Simon C. Increasing levels of estradiol are deleterious to embryonic implantation because they directly affect the embryo. Fertil Steril 2001;76:962-8.
17. Özçakir HT, Tavmergen EN, Terek MC. Relationship of follicle number, serum estradiol level, and other factors to clinical pregnancy rate in gonadotropin-induced intrauterine insemination cycles. Arch Gynecol Obstet 2002;266:18-20.
18. Fiçicioglu C, Kutlu T, Baglam E, Bakacak Z. Early follicular antimüllerian hormone as an indicator of ovarian reserve. Fertil Steril 2006;85:592–6.
19. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-mullerian hormone expression pattern in the human ovary: potential implication for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77–83.
20. Patrelli TS, Gizzo S, Sianesi N, Levati L, Pezzuto A, Ferrari B, et al. Anti-Mullerian hormone serum values and ovarian reserve: can it predict a decrease in fertility after ovarian stimulation by ART cycles? PLoS One 2012;7:e44571.
21. Choi MH, Yoo JH, Kim HO, Cha SH, Park CW, Yang KM, et al. Serum anti-Mullerian hormone levels as a predictor of the ovarian response and IVF outcomes. Clin Exp Reprod Med 2011;38:153-8.
22. Gleicher N, Weghofer A, Barad DH. Antimullerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve. Fertil Steril 2010;94:2824-7.
23. LaMarca A, Nelson SM, Sighinolfi G, Manno M, Baraldi E, Roli L, et al. Anti-Mullerian hormone-based prediction model for a live birth in assisted reproduction. Reprod Biomed Online 2011;22:341-9.
24. Sahmay S, Demirayak G, Guralp O, Ocal P, Senturk LM, Oral E, et al. Serum antimullerian hormone, follicle stimulating hormone and antral follicle count measurement cannot predict pregnancy rates in IVF/ICSI cycles. J Assist Reprod Genet 2012;29:589-95.
25. Mutlu MF, Erdem M, Erdem A, Yildiz S, Mutlu I, Arisoy O, et al. Antral follicle count determines poor ovarian response better than anti-Mullerian hormone but age is the only predictor for live birth in in vitro fertilization cycles. J Assisted Reproduction Genetics 2013;30:657-65.
26. Lin WQ, Yao LN, Zhang DX, Zhang W, Yang XJ, Yu R. The predictive value of anti-Mullerian hormone on embryo quality, blastocyst development, and pregnancy rate following in vitro fertilization embryo transfer (IVF-ET). J Assisted Reproduction Genetics 2013;30:649-55.
27. Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP. Anti-Müllerian hormone as a predictor of IVF outcome. Reprod Biomed Online 2007;14:602-10.
28. Penarrubia J, Fabregues F, Manau D, Creus M, Casals G, Casamitjana R, et al. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist–gonadotropin treatment. Hum Reprod 2005;20:915-22.
29. Durlinger ALL, Visser JA, Themmen APN. Regulation of ovarian function: the role of the anti-Mullerian hormone. Reproduction 2002;124:601-9.
30. Josso N, di Clemente N, Gouedard L. Anti-Mullerian hormone and its receptors. Mol Cell Endocrinol 2001;179:25–32.
31. Hattori Y, Sato T, Okada H, Saito C, Sugiura M. Comparison of follicular fluid and serum anti-Mullerian hormone levels as predictors of the outcome of assisted reproductive treatment. Eur J Obstet Gynecol Reprod Biol 2013;169:252-6.
32. Hodson D, Townsend J, Tortonese D. Characterization of the effects of prolactin in gonadotroph target cells. Biol Reprod 2010;83:1046-55.
33. Kostrzak A, Meczekalski B. Macroprolactinaemia. Pol Merkuriusz Lek 2010;29:47-9.
34. Bushe C, Bradley A, Pendlebury J. A review of hyperprolactinemia and severe mental illness: are there implications for clinical biochemistry? Ann Clin Biochem 2010;47:292-300.
35. Sonigo C, Bouilly J, Carré N, Tolle V, Caraty A, Tello J, et al. Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J Clin Invest 2012;122:3791-5.
36. McNeilly AS. Prolactin and ovarian function. In: Muller EE, MacLeod RM. eds. Neuroendocrine perspectives. Elsevier, Amsterdam; 1984. p. 279-16.
37. Oda T, Yoshimura Y, Takehara Y, Kohriyama S, Sano Y, Tanabe K, et al. Effects of prolactin on fertilization and cleavage of human oocytes. Horm Res 1991;35:33-8.
38. Gonen Y, Casper RF. Does transient hyperprolactinemia during ovarian hyperstimulation interfere with conception or pregnancy outcome? Fertil Steril 1989;51:1007-10.
39. Yoshimura Y, Nakamura Y, Yamada H, Ando M, Ubukata Y, Oda T, et al. Possible contribution of prolactin in the process of ovulation and oocyte maturation. Horm Res 1991;35:22-32.
40. Binart N, Helloco C, Ormandy CJ, Barra J, Clement-Lacroix P, Baran N, et al. Rescue of preimplantatory egg development and embryo implantation in prolactin receptor-deficient mice after progesterone administration. Endocrinology 2000;141:2691-7.
41. Shibli-Rahhal A, Schlechte J. Hyperprolactinemia, and infertility. Endocrinol Metab Clin North Am 2011;40:837-46.
42. Zhong L, D’Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, et al. The histone deacetylase SIRT6 regulates glucose homeostasis via Hif1α. Cell 2010;140:280-93.
43. Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature 2012;483:218-21.
44. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006;124:315-29.
45. Kanfi Y, Peshti V, Gil R, Naiman S, Nahum L, Levin E, et al. SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell 2010;9:162-73.
46. Zinman GE. Analysis of high-throughput genomic datasets across species. PhD dissertation submitted to school of computer science Carnegie Mellon University, Pennsylvania, USA; 2012. p. 73-5.
47. Zhang J, Fang L, Lu Z, Xiong J, Wu M, Shi L, et al. Are sirtuins markers of ovarian aging? Gene. 2015. doi: 10.1016/j.gene.2015.09.043. [Article in Press]
48. Kawahara TL, Michishita E, Adler AS, Damian M, Berber E, Lin M, et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappa B-dependent gene expression and organismal life span. Cell 2009;136:62-74.
49. Featherstone C, Jackson SP. a DNA repair protein with multiple cellular functions? Mutat Res 1999;434:3-15.
50. Lalithamma A, Changamma C. A Study on ovarian metabolic profiles in estradiol valerate administered aged female rats. Int J Pharm Pharm Sci 2013;5(Suppl 1):97-9.
230 Views | 488 Downloads
How to Cite
Al-hakeim, H. K., I. M. Jebur, and A. I. Rahim. “SIRT6 IS CORRELATED WITH ESTRADIOL IN WOMEN WITH IN VITRO FERTILIZATION FAILURE”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 8, no. 1, Nov. 2015, pp. 184-8,
Original Article(s)